Brain Stimulation Linked To Lower Sudden Death Risk In Epilepsy

What was studied

This paper was a systematic review, which means the authors gathered and combined results from earlier studies. They looked at sudden unexpected death in epilepsy (SUDEP) in people with drug-resistant epilepsy who were treated with 1 of 3 brain or nerve stimulation therapies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (DBS-ANT), and responsive neurostimulation (RNS).

The review searched major medical databases through January 2025. It included 18 studies with more than 44,000 patients and about 290,000 patient-years of follow-up. The authors counted or calculated SUDEP rates and compared them indirectly with published rates from drug-resistant epilepsy reference populations.

What they found

Across the included studies, SUDEP rates in people treated with neuromodulation were below the published rates reported in drug-resistant epilepsy reference populations. VNS studies reported about 1.7 to 4.1 SUDEP deaths per 1,000 patient-years. DBS-ANT studies reported about 1.62 to 2.0 per 1,000 patient-years. RNS studies reported about 2.0 to 3.5 per 1,000 patient-years.

The review says all 3 therapies were associated with SUDEP rates below the benchmark range for drug-resistant epilepsy, which was about 6.3 to 9.3 per 1,000 patient-years. VNS had the strongest evidence for a decline over time, including one very large study that found a statistically significant decline. The review also found that greater seizure reduction correlated inversely with SUDEP rates.

Limits of the evidence

This review cannot prove that these devices directly prevent SUDEP. The comparisons were indirect, not head-to-head trials against similar untreated patients.

The included studies may have used different methods to identify SUDEP, different follow-up times, and different patient populations. The abstract also notes that prospective registries with standardized SUDEP surveillance are needed to establish causality.

For families and caregivers

For families, this review suggests that VNS, DBS-ANT, and RNS are associated with lower SUDEP rates in people with drug-resistant epilepsy than expected DRE benchmark rates. That is encouraging, especially because SUDEP risk is higher in more severely affected groups.

Still, this does not mean a device guarantees protection from SUDEP. The findings fit with the idea that better seizure control may be linked with lower risk, but the study cannot prove cause and effect. Families may see this as one part of the bigger picture when discussing treatment goals and SUDEP risk with an epilepsy specialist.

What to watch next

Prospective registries with standardized SUDEP surveillance are needed to help establish whether these associations are causal.

Terms in this summary

SUDEP

Sudden unexpected death in epilepsy; a sudden death in a person with epilepsy when no other clear cause is found.

drug-resistant epilepsy

Epilepsy in which seizures continue despite trying appropriate seizure medicines.

neuromodulation

Treatment that uses electrical stimulation to change nerve or brain activity.

VNS

Vagus nerve stimulation, a device that sends electrical signals to the vagus nerve.

DBS-ANT

Deep brain stimulation of the anterior nucleus of the thalamus, a device that stimulates a specific brain area.

RNS

Responsive neurostimulation, a device that detects abnormal brain activity and gives stimulation in response.

patient-years

A way to measure follow-up time; for example, 100 people followed for 1 year equals 100 patient-years.

systematic review

A study that collects and summarizes results from multiple earlier studies using a planned method.